Its screen for selected variants of some disease-linked genes gives customers an incomplete picture of their risk—do they know?

A neurologist by training, Stefánsson founded Iceland-based deCODE Genetics to explore what the human genome can tell us about disease and our species’ evolution.

With three recent FDA approvals, and a number of Phase 3 trials ongoing, the drugs are seeing a surge in interest.

The agency gave personal genomics company 23andMe the green light to screen samples for breast cancer–related genetic mutations.

Researchers identify 72 novel genetic variants associated with breast cancer risk.

Members of the BabySeq Project discuss trial enrollment, preliminary findings.

Color Genomics announces a new, lower-cost BRCA mutation test, while Inserm and Quest Diagnostics reveal plans to pool patient data to investigate rare mutations.

In a large study, researchers find evidence to suggest that the type and location of a woman’s BRCA1/2 mutations may affect her cancer risk.

Myriad Genetics, the company originally behind tests for the cancer-associated BRCA mutations, is suing another competitor for patent infringement.